{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/prescribing-information/topical-sympathomimetics/","result":{"pageContext":{"chapter":{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics","depth":2,"htmlHeader":"<!-- begin field 8b6d745c-b0c4-46ac-9632-523d050173a5 --><h2>Topical sympathomimetics</h2><!-- end field 8b6d745c-b0c4-46ac-9632-523d050173a5 -->","summary":"","htmlStringContent":"<!-- begin item f7f89b3a-cc68-494b-85ea-b9bd9122c8ad --><!-- end item f7f89b3a-cc68-494b-85ea-b9bd9122c8ad -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8196c5eb-ad0a-5a5c-a40c-dbea3b79eb64","slug":"available-preparations","fullItemName":"Available preparations","depth":3,"htmlHeader":"<!-- begin field 2ee1b494-325f-447d-bdf7-172fbc1c1e0d --><h3>Which topical sympathomimetics are available for the treatment of glaucoma?</h3><!-- end field 2ee1b494-325f-447d-bdf7-172fbc1c1e0d -->","summary":"","htmlStringContent":"<!-- begin item a1761a96-056f-4616-9c62-fe4ebb712465 --><!-- begin field 6c6fb4b7-577f-4a58-9272-13ae6fa63640 --><ul><li>Brimonidine tartrate is a topical sympathomimetic drug used to treat glaucoma, typically in a person with glaucoma where a topical beta-blocker is inappropriate. The usual dose is one drop twice daily, approximately 12 hours apart.</li><li>Brimonidine tartrate is also available as a compound preparation containing timolol. This is typically used when timolol alone has not adequately controlled intraocular pressure (IOP). The usual dose is one drop twice daily, approximately 12 hours apart.</li><li>Apraclonidine is another sympathomimetic drug that is only used in special circumstances. For example, prior to laser or surgical treatment in people with glaucoma with IOP not adequately controlled by other drugs. It is generally not suitable for long-term use owing to loss of effect over several weeks, and a high incidence of local adverse effects.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 6c6fb4b7-577f-4a58-9272-13ae6fa63640 --><!-- end item a1761a96-056f-4616-9c62-fe4ebb712465 -->","subChapters":[]},{"id":"546b1313-09c9-5d92-a88b-c6132506e44a","slug":"action","fullItemName":"Action","depth":3,"htmlHeader":"<!-- begin field 7236358f-983b-42cc-b2a2-ccec97e0aadc --><h3>How do topical sympathomimetics work?</h3><!-- end field 7236358f-983b-42cc-b2a2-ccec97e0aadc -->","summary":"","htmlStringContent":"<!-- begin item 78df0b7b-de20-4644-b692-c12739233e80 --><!-- begin field 09f7c20a-6e0b-48f5-97c3-d94d38f8b0e7 --><ul><li>Topical sympathomimetics reduce intraocular pressure by decreasing aqueous humour production by an effect on ciliary epithelium and increasing uveoscleral outflow of aqueous humour.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 09f7c20a-6e0b-48f5-97c3-d94d38f8b0e7 --><!-- end item 78df0b7b-de20-4644-b692-c12739233e80 -->","subChapters":[]},{"id":"c6118eef-fc91-558d-919c-31631c503fe6","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 4135b7fb-d733-44a1-a750-4e5254a4170d --><h3>What are the cautions and contraindications when prescribing topical sympathomimetics?</h3><!-- end field 4135b7fb-d733-44a1-a750-4e5254a4170d -->","summary":"","htmlStringContent":"<!-- begin item acacb093-7b2a-4f42-8020-7056cf0f42c2 --><!-- begin field ed776b40-334a-418d-ac23-d9825c493610 --><ul><li><strong>Brimonidine tartrate is contraindicated</strong> in children under 2 years of age.</li><li><strong>Use brimonidine tartrate with caution</strong> in people with severe cardiovascular disease, cerebral or coronary insufficiency, Raynaud's syndrome, thromboangiitis obliterans, postural hypotension, depression, hepatic impairment, renal impairment, and in children aged 2–12 years (increased risk of drowsiness).</li><li><strong>For pregnant women,</strong> the manufacturer advises to avoid unless potential benefit outweighs risk.</li><li><strong>For breastfeeding women,</strong> the manufacturer advises to avoid.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field ed776b40-334a-418d-ac23-d9825c493610 --><!-- end item acacb093-7b2a-4f42-8020-7056cf0f42c2 -->","subChapters":[]},{"id":"82bdba29-729f-5173-b7ec-7bdfeb47b5cd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 014df03a-f42f-443e-9d85-5b7a2605e6bd --><h3>What key adverse effects are associated with topical sympathomimetics?</h3><!-- end field 014df03a-f42f-443e-9d85-5b7a2605e6bd -->","summary":"","htmlStringContent":"<!-- begin item b3f739f4-8ad2-4240-9f3b-bf27a187e2e2 --><!-- begin field 235c5653-0cfa-4b38-a92f-959eb0f00b7c --><ul><li><strong>Local adverse effects include:</strong><ul><li>Hyperaemia, burning, and stinging of the eyes.</li><li>Dry mouth and abnormal taste in the mouth, which are associated with drainage of the drug into the nasopharynx.</li><li>Allergic reaction to the active drug or preservative.</li></ul></li><li><strong>Systemic adverse effects</strong> are less common than local adverse effects and include: dry mouth, gastrointestinal disturbances, headache, drowsiness, dizziness, malaise, arrhythmias, depression, dyspnoea, hypertension, hypotension, angioedema, syncope, and insomnia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 235c5653-0cfa-4b38-a92f-959eb0f00b7c --><!-- end item b3f739f4-8ad2-4240-9f3b-bf27a187e2e2 -->","subChapters":[]},{"id":"56c7128e-a786-530e-aa56-f034300b1a2c","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field 6e6adfe9-ffc1-406f-8bf4-ad63f8f02eaf --><h3>What drug interactions are important with topical sympathomimetics?</h3><!-- end field 6e6adfe9-ffc1-406f-8bf4-ad63f8f02eaf -->","summary":"","htmlStringContent":"<!-- begin item d4360a7b-200b-4ab1-8e9c-0449f1ee03ff --><!-- begin field 944579f3-4b40-4740-9445-dbc563b1076f --><ul><li><strong>Topical sympathomimetics should not be used with:</strong><ul><li>Monoamine oxidase inhibitor antidepressants owing to the risk of hypertensive crisis.</li><li>Antidepressants that affect noradrenagic transmission (for example, tricyclic antidepressants and mianserin).</li></ul></li><li><strong>Central nervous system (CNS) depressants</strong> — monitor closely when topical sympathomimetics are used with CNS depressants, such as alcohol, barbiturates, opiates, sedatives, or anaesthetics.<ul><li>CNS depressants could potentiate the effects of topical sympathomimetics.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>]</p><!-- end field 944579f3-4b40-4740-9445-dbc563b1076f --><!-- end item d4360a7b-200b-4ab1-8e9c-0449f1ee03ff -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}